Jorge J Castillo, Joshua N Gustine, Andrew Keezer, Kirsten Meid, Catherine A Flynn, Toni E Dubeau, Gloria Chan, Jiaji Chen, Maria G Demos, Maria L Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Lian Xu, Guang Yang, Zachary R Hunter, Steven P Treon
Rituximab-containing regimens are commonly used for frontline therapy in patients with symptomatic Waldenström macroglobulinemia (WM). We had observed that a portion of WM patients experienced deepening of response months to years after therapy completion. We carried a retrospective study aimed at describing this phenomenon. We gathered baseline data, and responses at end of induction, end of maintenance and best response. Deepening of response was defined as ≥25% decrease in serum IgM achieved at a later time from therapy completion...
April 2020: American Journal of Hematology